On Monday, the FDA warned that popular GLP-1 weight-loss drugs carry a potential risk of non-arteritic anterior ischemic optic neuropathy, a rare and serious eye condition causing sudden vision loss with no proven treatments. Drug companies must now inform patients and doctors of this risk.